Amyris
Emeryville, US · Delaware corporation · 3 known investors
Amyris develops a biomanufacturing platform that uses fermentation and microbial engineering to produce natural ingredients and rare compounds at scale for partners across industries such as specialty chemicals, food ingredients, and consumer products. Founded in 2003, the company focuses on sustainable, bio-based sourcing of molecules.
Advanced ManufacturingBiotechCleantechNew Materials
Founders & leadership
NK
NICHOLAS KHADDERSenior Vice President, General Counsel & Secretaryformer
RA
RAFFI ASADORIANChief Financial Officerformer
JC
Joel CherryPresident, Research & Developmentformer
TT
Tamara TompkinsExecutive Vice President, General Counselformer
JM
John MeloPresident & Chief Executive Officer2007–2023
PD
Paulo DinizChief Financial Officerformer
SK
Samir KaulNamed on SEC filingformer
AL
Arthur LevinsonNamed on SEC filingformer
JH
Jeryl HillemanChief Financial Officerformer
RA
Ralph AlexanderNamed on SEC filingformer
PP
Patrick PichetteNamed on SEC filingformer
Board
JD
Investors · 3
Reported raises · per SEC filings
Form D private placements$1.3B disclosed across 38 rounds · 2012–2022
▶$8MraisedSep 2022 · 1 investors · ManufacturingRule 506(b)
▶$8MraisedSep 2022 · 1 investors · Manufacturing
Rule 506(b)Officers, directors & promoters on the filing
- NICOLE KELSEYExecutive Officer
- HERMANUS KIEFTENBELDExecutive Officer
- EDUARDO ALVAREZExecutive Officer
- JOHN MELOExecutive Officer, Director
- FRANK KUNGDirector
- LISA QIDirector
- JULIE WASHINGTONDirector
- PHILIP EYKERMANDirector
- GEOFFREY DUYKDirector
- RYAN PANCHADSARAMDirector
- ANA DUTRADirector
- JAMES MCCANNDirector
- STEVEN MILLSDirector
- L JOHN DOERRDirector
- Offering amount
- $8M
- Amount sold
- $8M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$200MraisedJun 2020 · 53 investors · ManufacturingRule 506(b)
▶$200MraisedJun 2020 · 53 investors · Manufacturing
Rule 506(b)Officers, directors & promoters on the filing
- JAMES MCCANNDirector
- STEVEN MILLSDirector
- GEOFFREY DUYKDirector
- LISA QIDirector
- PHILIP EYKERMANDirector
- JOHN MELOExecutive Officer, Director
- L JOHN DOERRDirector
- NICOLE KELSEYExecutive Officer
- CHRISTOPH GOPPELSROEDERDirector
- EDUARDO ALVAREZExecutive Officer
- CAROLE PIWNICADirector
- HAN KEIFTENBELDExecutive Officer
- FRANK KUNGDirector
- PATRICK YANGDirector
- Offering amount
- $200M
- Amount sold
- $200M
- Sales commissions
- $9M
- Placement agents
- JEFFERIES LLC, COWEN AND COMPANY, LLC, OPPENHEIMER & CO. INC.
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$93.7MraisedFeb 2020 · 7 investors · ManufacturingRule 506(b)
▶$93.7MraisedFeb 2020 · 7 investors · Manufacturing
Rule 506(b)Officers, directors & promoters on the filing
- JOHN MELOExecutive Officer, Director
- EDUARDO ALVAREZExecutive Officer
- NICOLE KELSEYExecutive Officer
- KATHLEEN VALIASEKExecutive Officer
- L JOHN DOERRDirector
- GEOFFREY DUYKDirector
- PHILIP EYKERMANDirector
- CHRISTOPH GOPPELSROEDERDirector
- FRANK KUNGDirector
- CAROLE PIWNICADirector
- STEVEN MILLSDirector
- R NEIL WILLIAMSDirector
- PATRICK YANGDirector
- JONATHAN WOLTERExecutive Officer
- JAMES MCCANNDirector
- LISA QIDirector
- Offering amount
- $93.7M
- Amount sold
- $93.7M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.8MraisedJan 2020 · 4 investors · ManufacturingRule 506(b)
▶$9.8MraisedJan 2020 · 4 investors · Manufacturing
Rule 506(b)Officers, directors & promoters on the filing
- CAROLE PIWNICADirector
- STEVEN MILLSDirector
- R NEIL WILLIAMSDirector
- PATRICK YANGDirector
- JONATHAN WOLTERExecutive Officer
- LISA QIDirector
- FRANK KUNGDirector
- CHRISTOPH GOPPELSROEDERDirector
- L JOHN DOERRDirector
- GEOFFREY DUYKDirector
- PHILIP EYKERMANDirector
- JAMES MCCANNDirector
- JOHN MELOExecutive Officer, Director
- EDUARDO ALVAREZExecutive Officer
- NICOLE KELSEYExecutive Officer
- KATHLEEN VALIASEKExecutive Officer
- Offering amount
- $9.8M
- Amount sold
- $9.8M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.9MraisedDec 2019 · 1 investors · ManufacturingRule 506(b)
▶$3.9MraisedDec 2019 · 1 investors · Manufacturing
Rule 506(b)Officers, directors & promoters on the filing
- JOHN MELOExecutive Officer, Director
- GEOFFREY DUYKDirector
- LISA QIDirector
- JAMES MCCANNDirector
- JONATHAN WOLTERExecutive Officer
- PATRICK YANGDirector
- R NEIL WILLIAMSDirector
- STEVEN MILLSDirector
- CAROLE PIWNICADirector
- FRANK KUNGDirector
- CHRISTOPH GOPPELSROEDERDirector
- PHILIP EYKERMANDirector
- L JOHN DOERRDirector
- KATHLEEN VALIASEKExecutive Officer
- NICOLE KELSEYExecutive Officer
- EDUARDO ALVAREZExecutive Officer
- Offering amount
- $3.9M
- Amount sold
- $3.9M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.8MraisedNov 2019 · 2 investors · ManufacturingRule 506(b)
▶$7.8MraisedNov 2019 · 2 investors · Manufacturing
Rule 506(b)Officers, directors & promoters on the filing
- JAMES MCCANNDirector
- LISA QIDirector
- JOHN MELOExecutive Officer, Director
- EDUARDO ALVAREZExecutive Officer
- NICOLE KELSEYExecutive Officer
- KATHLEEN VALIASEKExecutive Officer
- L JOHN DOERRDirector
- GEOFFREY DUYKDirector
- PHILIP EYKERMANDirector
- CHRISTOPH GOPPELSROEDERDirector
- FRANK KUNGDirector
- CAROLE PIWNICADirector
- STEVEN MILLSDirector
- R NEIL WILLIAMSDirector
- PATRICK YANGDirector
- JONATHAN WOLTERExecutive Officer
- Offering amount
- $7.8M
- Amount sold
- $7.8M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.7MraisedNov 2019 · 1 investors · ManufacturingRule 506(b)
▶$7.7MraisedNov 2019 · 1 investors · Manufacturing
Rule 506(b)Officers, directors & promoters on the filing
- JAMES MCCANNDirector
- LISA QIDirector
- EDUARDO ALVAREZExecutive Officer
- JOHN MELOExecutive Officer, Director
- JONATHAN WOLTERExecutive Officer
- PATRICK YANGDirector
- R NEIL WILLIAMSDirector
- STEVEN MILLSDirector
- CAROLE PIWNICADirector
- FRANK KUNGDirector
- CHRISTOPH GOPPELSROEDERDirector
- NICOLE KELSEYExecutive Officer
- GEOFFREY DUYKDirector
- PHILIP EYKERMANDirector
- KATHLEEN VALIASEKExecutive Officer
- L JOHN DOERRDirector
- Offering amount
- $7.7M
- Amount sold
- $7.7M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.7MraisedOct 2019 · 1 investors · ManufacturingRule 506(b)
▶$5.7MraisedOct 2019 · 1 investors · Manufacturing
Rule 506(b)Officers, directors & promoters on the filing
- L JOHN DOERRDirector
- GEOFFREY DUYKDirector
- PHILIP EYKERMANDirector
- CHRISTOPH GOPPELSROEDERDirector
- FRANK KUNGDirector
- JOHN MELOExecutive Officer, Director
- EDUARDO ALVAREZExecutive Officer
- KATHLEEN VALIASEKExecutive Officer
- NICOLE KELSEYExecutive Officer
- LISA QIDirector
- CAROLE PIWNICADirector
- STEVEN MILLSDirector
- R NEIL WILLIAMSDirector
- PATRICK YANGDirector
- JONATHAN WOLTERExecutive Officer
- JAMES MCCANNDirector
- Offering amount
- $5.7M
- Amount sold
- $5.7M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapAlumis19 shared keywordsAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Fortis Life Sciences11 shared keywordsFortis Life Sciences develops and manufactures immunodetection reagents including primary and secondary antibodies, ELISA kits, antigens, engineered nanoparticles, and VHH single-domain antibody libraries. It supplies biopharma, diagnostics, research, and applied technology customers globally from North American manufacturing and R&D sites.
Companies competing with Amyris for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Amyris do?
- Amyris develops a biomanufacturing platform that uses fermentation and microbial engineering to produce natural ingredients and rare compounds at scale for partners across industries such as specialty chemicals, food ingredients, and consumer products. Founded in 2003, the company focuses on sustainable, bio-based sourcing of molecules.
- Who are Amyris's investors?
- Amyris's investors include Kleiner Perkins, R7 Partners, Vivo Capital.
- How much funding has Amyris raised?
- Amyris has disclosed $1.3B raised across 38 rounds.
- Where is Amyris headquartered?
- Amyris is headquartered in Emeryville, US.